Login to Your Account

Other News To Note

Tuesday, March 26, 2013
• United Therapeutics Corp., of Silver Spring, Md., said it received a second complete response letter (CRL) from the FDA, declining to approve its new drug application (NDA) for treprostinil diolamine extended-release tablets (oral treprostinil) for the treatment of pulmonary arterial hypertension (PAH).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription